Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

doi:10.1200/JCO.19.02314

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Apr 2020

Treon Steven P, Xu Lian, Guerrera Maria Luisa, Jimenez Cristina, Hunter Zachary R, Liu Xia, Demos Maria, Gustine Joshua, Chan Gloria, Munshi Manit, Tsakmaklis Nicholas, Chen Jiaji G, Kofides Amanda, Sklavenitis-Pistofidis Romanos, Bustoros Mark, Keezer Andrew, Meid Kirsten, Patterson Christopher J, Sacco Antonio, Roccaro Aldo, Branagan Andrew R, Yang Guang, Ghobrial Irene M, Castillo Jorge J

Abstract excerpt

Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A (17%), and CD79B (8%-15%). Deletions involving chromosome 6q are common in patients with mutated MYD88 and include genes that modulate NFKB, BCL2, Bruton tyrosine kinase (BTK), and apoptosis. Patients with wild-type MYD88 WM show an increased risk of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Genomics

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Pathology, Molecular

Share to Receptors, CXCR4

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed Open full text

Identifiers

PMID: 32083995
DOI: 10.1200/JCO.19.02314
PMCID: PMC7351339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.PMID 32083995Read ↗

Genomic Landscape of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Clinical application of genomics in Waldenström macroglobulinemia.Semantic proximity Read ↗

Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.Semantic proximity Read ↗

New treatment strategies for Waldenström macroglobulinemia.Semantic proximity Read ↗

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.Semantic proximity Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Semantic proximity Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.Semantic proximity Read ↗

Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.